CoVaRR-Net Funded Publications
CoVaRR-Net was extremely productive with regards to scientific outputs relative to the research funding investments it received. In its four years of operation, the Network’s members produced 139 peer-reviewed research publications, 12 preprints and 15 other types of publications, including live systematic reviews and public health recommendations.
In an effort to make the science more understandable to a wider audience, CoVaRR-Net wrote lay summaries of many of its funded publications, listed below.
Regulatory dissection of the severe COVID-19 risk locus introgressed by Neanderthals
People who have COVID-19 can show a wide variety of symptoms ranging from nothing to very severe and even lethal outcomes.
Clinical and serological predictors of Post COVID-19 Condition: Findings from a Canadian prospective cohort study
With this living evidence profile, we aim to evaluate accumulating evidence related to the animal and zoonotic characteristics of the mpox virus, understand their relevance to the Canadian context and identify important gaps in evidence.
The metallodrug BOLD-100 is a potent inhibitor of SARS-CoV-2 replication and has broad-acting antiviral activity
The COVID-19 pandemic has emphasized the urgent need for new drugs to treat patients. Some metal-based drugs interact with genetic material and proteins in the body and have shown promise against cancer and infections.
Detection of prevalent SARS-CoV-2 variant lineages in wastewater and clinical sequences from cities in Québec, Canada
The ongoing pandemic wave caused by the Omicron variant of SARS-CoV-2 has overwhelmed PCR testing capacity in many parts of the world, including Canada.
Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection
Establishing immunity in the oral and nasal cavities is an important first line of defense against the development of symptoms and illness due to COVID-19 and associated variants, which results from infection of the upper airway.
Prevalence of Low-Frequency, Antiviral Resistance Variants in SARS-CoV-2 Isolates in Ontario, Canada, 2020-23
We extended our SARS-CoV-2 inhibitor studies on alotaketal C (a sesterterpenoid previously discovered in extracts of the marine sponge Phorbas sp. collected in Howe Sound, British Columbia) to explore the proposed host-directed ACE2 shedding antiviral mechanism of action.
Cohort profile: Stop the Spread Ottawa (SSO)—a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination
Since December 2019, the COVID-19 virus has infected over 300 million people and caused more than 5.4 million deaths worldwide. Global research efforts are ongoing to describe the strength and duration of immune response generated by natural infection and/or vaccination among different groups of people, including individuals with immunocompromising conditions and people with PASC (post-acute sequelae of COVID-19).
Synthetic Analogs of the Sponge Sesterterpenoid Alotaketal C are Potent Inhibitors of SARS-CoV-2 Omicron BA.1 and BA.5 Infections of Human Lung Cells
We extended our SARS-CoV-2 inhibitor studies on alotaketal C (a sesterterpenoid previously discovered in extracts of the marine sponge Phorbas sp. collected in Howe Sound, British Columbia) to explore the proposed host-directed ACE2 shedding antiviral mechanism of action.
Nanoplasmonic amplification in microfluidics enables accelerated colorimetric quantification of nucleic acid biomarkers from pathogens
Readily available, accurate, rapid diagnostic technologies will be needed to contain emerging and re-emerging pandemics. Although nucleic acid amplification assays (PCR) are the current gold standard, they require lengthy preparatory steps.